Supercharged immune cells aim to stop leukemia relapse after transplant

NCT ID NCT06158828

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving special 'memory-like' natural killer (NK) cells after a stem cell transplant can help prevent relapse in children and adults with high-risk acute myeloid leukemia (AML). The NK cells come from the same donor as the transplant and are boosted in the lab to be stronger. The trial will check if this treatment is safe and possible to make, and whether it improves survival and reduces side effects like graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: memory-like natural killer (NK) cells
What this could lead to: If successful, this approach could lower the chance of leukemia coming back after a stem cell transplant, improving long-term survival for children and adults with high-risk AML.
What could go wrong: This is an early-phase trial with only 68 participants, so results may not apply to everyone. Risks include graft-versus-host disease, infection, or the NK cells not working as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia childhood acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ACUTE MYELOID LEUKEMIA, PEDIATRIC AML AML, CHILDHOOD

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.